Skip to main content
. 2016 Sep 24;7(45):73101–73113. doi: 10.18632/oncotarget.12231

Figure 4. The activation status of Src, RhoA, ROCK1, P38, ERK, and AKT in the myeloma cells treated with FAK inhibitor or myeloma cells with suppressed and overexpressed SH3GL3.

Figure 4

(A) The phosphorylated protein levels of FAK, PI3K, Src, RhoA, ROCK1, and P38 in the U266 cells treated with FAK inhibitor were decreased. (B) Representative blots showed the total and phosphorylated protein levels of Src, RhoA, ROCK1, P38, ERK and AKT in the U266 cells infected with SH3GL3 shRNA. (C) Representative blots showed the total and phosphorylated protein levels of Src, RhoA, ROCK1, P38, ERK and AKT in the U266 cells infected with SH3GL3 shRNA in the H929 cells infected with SH3GL3 cDNA. β-actin is loading control.